同源康醫藥發布艾多替尼片非小細胞肺癌II期臨牀試驗結果

阿斯達克財經

2025/08/14

同源康醫藥(02410.HK) 表示，自主研發的創新藥物艾多替尼片(TY-9591)治療EGFR變異型非小細胞肺癌(NSCLC)的關鍵性II期註冊臨牀試驗(NCT05948813)結果，已在國際肺癌研究協會(IASLC)舉辦的2025年世界肺癌會議(WCLC)上被接受為minioral報告(MA08.06)，並將在會議期間進行專題彙報。艾多替尼片(TY-9591)是公司開發的高選擇性小分子抑制劑，...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2559938863"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559938863\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559938863?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240819111846106_s.jpg","is_english":false,"pubTime":"2025-08-14 08:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559938863","market":"hk","top_or_hot":-1,"title":"同源康醫藥發布艾多替尼片非小細胞肺癌II期臨牀試驗結果","media":"阿斯達克財經","content":"<div>\n<p>同源康醫藥(02410.HK) 表示，自主研發的創新藥物艾多替尼片(TY-9591)治療EGFR變異型非小細胞肺癌(NSCLC)的關鍵性II期註冊臨牀試驗(NCT05948813)結果，已在國際肺癌研究協會(IASLC)舉辦的2025年世界肺癌會議(WCLC)上被接受為minioral報告(MA08.06)，並將在會議期間進行專題彙報。艾多替尼片(TY-9591)是公司開發的高選擇性小分子抑制劑，...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1460867/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>同源康醫藥發布艾多替尼片非小細胞肺癌II期臨牀試驗結果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n同源康醫藥發布艾多替尼片非小細胞肺癌II期臨牀試驗結果\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2025-08-14 08:22</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>同源康醫藥(02410.HK) 表示，自主研發的創新藥物艾多替尼片(TY-9591)治療EGFR變異型非小細胞肺癌(NSCLC)的關鍵性II期註冊臨牀試驗(NCT05948813)結果，已在國際肺癌研究協會(IASLC)舉辦的2025年世界肺癌會議(WCLC)上被接受為minioral報告(MA08.06)，並將在會議期間進行專題彙報。艾多替尼片(TY-9591)是公司開發的高選擇性小分子抑制劑，...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1460867/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1460867/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1460867/latest-news/AAFN","article_id":"2559938863","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240819111846106_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1460867/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2559938863","pubTimestamp":1755130920,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"同源康醫藥表示，自主研發的創新藥物艾多替尼片治療EGFR變異型非小細胞肺癌的關鍵性II期註冊臨床試驗結果，已在國際肺癌研究協會舉辦的2025年世界肺癌會議上被接受為minioral報告，並將在會議期間進行專題彙報。艾多替尼片是公司開發的高選擇性小分子抑制劑，以經典EGFR基因突變為靶點，旨在滿足在當前治療標準下對非小細胞肺癌腦轉移瘤尚未得到滿足的臨床需求。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","02410":"同源康医药-B","BK1515":"抗疫概念"},"translate_title":"Tongyuankang Pharmaceutical (02410. HK) releases the results of phase II clinical trial of idotinib tablets for non-small cell lung cancer","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02410":1},"content_text":"同源康醫藥(02410.HK) 表示，自主研發的創新藥物艾多替尼片(TY-9591)治療EGFR變異型非小細胞肺癌(NSCLC)的關鍵性II期註冊臨床試驗(NCT05948813)結果，已在國際肺癌研究協會(IASLC)舉辦的2025年世界肺癌會議(WCLC)上被接受為minioral報告(MA08.06)，並將在會議期間進行專題彙報。艾多替尼片(TY-9591)是公司開發的高選擇性小分子抑制劑，以經典EGFR基因突變為靶點，旨在滿足在當前治療標準下對非小細胞肺癌腦轉移瘤尚未得到滿足的臨床需求。研究表明，艾多替尼作為研發的新一代EGFR-TKI，對控制腦轉移病灶和緩解病情顯示優異的療效，有望為伴腦轉移的EGFR突變NSCLC患者提供新的、更有效的一線治療選擇。公司表示，研究團隊將持續跟進，以獲取成熟的iPFS、PFS及OS數據，推動該創新藥儘快造福患者。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}